rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

InfuSystems Holdings, Inc.

INFU · NYSE American

Health CareMedical DevicesLeading

INFU stood above a rising 150-day average in 25 of the last 52 weekly readings, including each of the last 11 weeks. It is 26.8% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$301K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
99 (+7)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 25 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$342K$0$240KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months5
Sale orders, 12 months0
Buyers · sellers3 · 0
WhoDidSharesTraded
Carrie LachancePresident and CEObought1,000at $8.4611 May 2026filed 12 May 2026
Barry G. SteeleExecutive VP and CFObought7,000at $8.718 May 2026filed 12 May 2026
Carrie LachancePresident and CEObought2,000at $8.838 May 2026filed 12 May 2026
Paul Andrew GendronDirectorbought5,000at $8.888 May 2026filed 12 May 2026
Barry G. SteeleExecutive VP and CFObought2,064at $9.162 Mar 2026filed 2 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders99+7 on the quarter
New · exited29 · 22
Reported value$137.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20261,585,415$15.3M+968,829+157.1%
Minerva Advisors LLCadded · filed 12 Aug 20261,348,617$13.0M+144,512+12.0%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.reduced · filed 14 Aug 2026834,750$8.1M-3,175−0.4%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026790,775$7.6M-69,488−8.1%
HEARTLAND ADVISORS INCadded · filed 11 Aug 2026700,000$6.8M+190,000+37.3%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 2026675,028$6.5M+202,007+42.7%
First Eagle Investment Management, LLCreduced · filed 5 Aug 2026620,000$6.0M-101,371−14.1%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026599,289$5.8M+5,001+0.8%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 2026543,009$5.2M-23,800−4.2%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026496,059$4.8M+277,614+127.1%
31 Mar 2023 – 30 Jun 2026
557697Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Jerod Funke Company insiderEVP-Chief HR Officer · last 9 Oct 20261 · 0
Scott Shuda Company insiderDirector · last 10 Sep 202612 · 1
Addam Chupa Company insiderExecutive VP and CIO · last 18 May 20261 · 0
Barry G. Steele Company insiderExecutive VP and CFO · last 18 May 202610 · 0
Carrie Lachance Company insiderPresident and CEO · last 18 May 20267 · 0
Beverly A. Huss Company insiderDirector · last 12 May 20261 · 0
John J. Sviokla Company insiderDirector · last 12 May 20260 · 0
Kenneth D. Eichenbaum Company insiderDirector · last 12 May 20262 · 0
Paul Andrew Gendron Company insiderDirector · last 12 May 20265 · 0
Ronald T. Hundzinski Company insiderDirector · last 12 May 20261 · 0
Richard Dilorio Company insiderChief Executive Officer · last 17 May 20254 · 7
Ralph F. Boyd, Jr. Company insiderDirector · last 23 May 20241 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

Awards1
Total$69K
Latest1 Nov 2024

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202556.0%
Operating profit marginFY 2025 · to 31 Dec 20258.3%
Free cash flow marginFY 2025 · to 31 Dec 202516.6%
Return on capital employedFY 2025 · to 31 Dec 202514.8%
Cash conversionFY 2025 · to 31 Dec 2025368%
Debt to equityFY 2025 · to 31 Dec 20250.34×
Share count trendFY 2025 · to 25 Feb 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.2M
Free cash flowFY 2025 · to 31 Dec 2025$23.8M

Analyst forecasts

No analyst forecasts yet.